TrialDiabetes, obesity & metabolism2021

Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial.

Katsumi Iizuka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.